LGALS9 and hepatocellular carcinoma: Thus, the aims of our study were to examine how circulating levels of PD-L1 and Gal-9 compare to tissue expression of these molecules and whether circulating levels have the potential to replace tissue expression, or add to tissue expression, as potential immune biomarkers in HCC patients undergoing surgical resection.